Sunil Patel, MD
Hematology · Houston, TXNPI 1679666473
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,870 of the $4,946 with a category attached, or 78.3%. 13 manufacturers reported payments, led by Sirtex Medical Inc at 55.5% of the total. Reporting peaked in 2023 at $2,846 and has fallen 95.8% since, to $120 in 2025.
Across 31 payments — averaging $159.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$3K
- Johnson & Johnson$1K
- Athenex Pharmaceutical Division, LLC$350
- AstraZeneca$156
- Bristol Myers Squibb$149
- Genentech USA, Inc.$131
- plus $246 from 7 others
Across 147 payments — averaging $24,277 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.8M
- AstraZeneca$291K
- Merck$176K
- Eli Lilly$167K
- Genentech, Inc.$138K
What the payments were for
- Consulting fees$3,87078%
- Speaking & faculty fees$3507%
- Food & beverage$66613%
- Education$601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 2 | $2,744 |
| Johnson & Johnson | 1 | $1,170 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| AstraZeneca | 10 | $156 |
| Bristol Myers Squibb | 2 | $149 |
| Genentech USA, Inc. | 6 | $131 |
| Comsort, Inc | 1 | $100 |
| Genentech, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 1 | $37 |
| Blueprint Medicines Corporation | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$2,744
- IMBRUVICA$1,170
- KEYTRUDA$100
How this compares
$4,946 in reported general payments places this provider in the 60th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 59 | $659,893 |
| RevlimidLenalidomide | 52 | $644,208 |
| Abiraterone Acetate | 140 | $577,650 |
| ImbruvicaIbrutinib | 26 | $424,993 |
| PomalystPomalidomide | 16 | $378,759 |
| BrukinsaZanubrutinib | 16 | $230,498 |
| TasignaNilotinib Hcl | 24 | $229,448 |
| XtandiEnzalutamide | 16 | $209,634 |
| TagrissoOsimertinib Mesylate | 12 | $204,048 |
| ErleadaApalutamide | 12 | $179,238 |
| EliquisApixaban | 149 | $103,236 |
| Imatinib Mesylate | 17 | $102,091 |
| XareltoRivaroxaban | 24 | $28,976 |
| Exemestane | 15 | $7,933 |
| Anastrozole | 127 | $5,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $149 | $644,20852 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $37 | $378,75916 claims |
| Johnson & JohnsonErleada, Xarelto | $1,170 | $208,21436 claims |
| AstraZenecaTagrisso | $156 | $204,04812 claims |
| PfizerEliquis | $11 | $103,236149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 97 hematology providers in Texas.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Sa WangHouston$27K
- Uday PopatHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.